Hypoxia News and Research

RSS

Hypoxia is a condition in which there is a decrease in the oxygen supply to a tissue. In cancer treatment, the level of hypoxia in a tumor may help predict the response of the tumor to the treatment.

FG-4592 oral anemia therapy receives CTA approval from SFDA

FibroGen, Inc., today announced that its investigational oral anemia therapy, FG-4592, received Clinical Trial Application (CTA) approval from the Chinese State Food and Drug Administration (SFDA) to commence clinical development for the treatment of anemia associated with chronic kidney disease (CKD) in the People's Republic of China.

21 Sep 2010

Lofty altitudes increase prevalence of suicides

The Intermountain West is renowned for the beauty of its towering mountains and high deserts, but according to new research from an investigator with the University of Utah Brain Institute the region's lofty altitudes significantly influence a deadly problem: the high prevalence of suicides in this part of the country.

16 Sep 2010

Researchers unveil watercress compound can block pathway for cancer development

The research, unveiled at a press conference today (14 September 2010), shows that the watercress compound is able to interfere with the function of a protein which plays a critical role in cancer development.

15 Sep 2010

Positive results from YM BioSciences' CYT997 Phase I study for vascular disruption in tumors

YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.

8 Sep 2010

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic osteoarthritis knee pain have been published by Clinical Drug Investigation.

31 Aug 2010

Researchers identify molecule to slow down dysfunctional immune response in hemorrhagic shock

Researchers have isolated a molecule, small enough to be used as a drug, that can shut down a dysfunctional immune response that causes deadly hemorrhagic shock, results in delayed death of heart attack patients, promotes rejection of transplanted organs and destroys joints in patients with rheumatoid arthritis, according to a paper published in Molecular Immunology.

27 Aug 2010

FibroGen announces study results of recombinant human type III collagen in corneal damage

FibroGen, Inc., today announced results of a 2-year clinical study demonstrating that surgical implantation of biosynthetic corneas formulated with the company's proprietary recombinant human type III collagen (rhCIII) restored vision and promoted nerve regeneration (restoring sensitivity) in patients who had corneal damage and significant vision loss.

26 Aug 2010

Human umbilical cord blood cells appear to protect astrocytes from cell death: Research

Human umbilical cord blood cells (HUCB) used to treat cultured rat brain cells (astrocytes) deprived of oxygen appear to protect astrocytes from cell death after stroke-like damage, reports a team of researchers from the University of South Florida (USF) Department of Neurosurgery and Brain Repair.

25 Aug 2010

AHRQ grant allows Premier Perinatal Safety Initiative to develop birth-related injury reduction tehniques

The Department of Health & Human Services' Agency for Healthcare Research and Quality (AHRQ) has awarded a three-year demonstration grant for not-for-profit entities to Fairview Health Services in Minneapolis to extend a national collaborative that is reducing birth-related injuries.

20 Aug 2010

Aeolus completes $1.0M financing to initiate human clinical studies of AEOL 10150 for cancer

Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.0 million financing with two existing institutional shareholders, both of which are affiliates of Xmark Opportunity Partners, LLC.

13 Aug 2010

Scientists awarded $348,037 to study causes, effects of hypoxia in Green Bay

Scientists researching the causes and effects of hypoxia in Green Bay, part of Lake Michigan, Wisc., have been awarded $348,037 for the first year of an anticipated four-year $1,367,300 project through NOAA's Coastal Hypoxia Research Program. Hypoxia within Green Bay has been a problem for decades, and recent evidence suggests that it may be worsening, with the potential for "dead zones" and fish kills to become both more frequent and more extensive with a changing climate.

12 Aug 2010

Researchers suggest Hsp70 can reverse Diabetic peripheral neuropathy

Researchers have been able to use a common chaperone protein, Hsp70, to reverse the loss of function in the nerves of mice with diabetes.Writing in ASN NEURO, Michael J. Urban and colleagues at the University of Kansas suggest that Hsp70 could be used in the future to cure the loss of feeling in the limbs that afflicts many diabetics.

12 Aug 2010

Synta second-quarter net loss increases to $9.1 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended June 30, 2010.

10 Aug 2010

Endo to acquire Penwest for $5.00 per share

Endo Pharmaceuticals today announced actions designed to advance the company's leadership and growth in pain management, including an agreement to acquire all outstanding shares of Penwest Pharmaceuticals for $5.00 in cash per share, or an estimated enterprise value of approximately $144 million at the time of deal close. Penwest has been working with Endo since 1997 on the development and commercialization of OPANA® ER and receives a royalty stream on net sales of the product.

10 Aug 2010

Diffusion Pharmaceuticals receives patent for drug formulation

Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,759,506 entitled "Bipolar Trans Carotenoid Salts and Their Uses." This patent includes drug formulation and use claims relating to Diffusion's entire family of first-in-class new chemical entities. Diffusion Pharmaceuticals is commercializing this family of first-in-class drug candidates to treat serious or life-threatening medical conditions characterized by hypoxia or oxygen deprivation at the cellular level.

3 Aug 2010

Researchers receive $4.7M contract to develop drugs to improve soldiers' performance at high altitude

Jonathan Stamler, MD, Director of the Institute for Transformative Molecular Medicine and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at the Case Western Reserve University and University Hospitals Harrington-McLaughlin Heart & Vascular Institute, has recently received a $4.7 million contract from the Defense Advanced Research Projects Agency to fund the development of a new class of drugs that will selectively dilate blood cells under hypoxia (lack of oxygen in the body's tissues) and thereby enhance soldiers' performance at high altitude.

31 Jul 2010

Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine

Dendreon Corporation announced today the publication of data from the pivotal Phase 3 IMPACT study in the New England Journal of Medicine, showing that PROVENGE (sipuleucel-T) demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer. The manuscript is published in the July 29, 2010 issue of the journal.

29 Jul 2010

Morphine blocks new blood vessel and tumor growth: Study

Current research suggests that taking morphine can block new blood vessel and tumor growth. The related report by Koodie et al, "Morphine suppresses tumor angiogenesis through a HIF1α/p38MAPK pathway," appears in the August 2010 issue of the American Journal of Pathology.

28 Jul 2010

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

A Phase 3 open-label study, recently published online by Pain Practice, has compared tapentadol extended release tablets, an investigational pain medication, to an existing prescription pain medication, oxycodone controlled release tablets.

20 Jul 2010

An overview of AAPM annual meeting

AAPM is the premier organization in medical physics, a broadly-based scientific and professional discipline encompassing physics principles and applications in medicine and biology. Its membership includes medical physicists who specialize in research that develops cutting-edge technologies and board-certified clinical medical physicists who apply these technologies in community hospitals, clinics, and academic medical centers.

16 Jul 2010